🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

3,061 results for “Bio” Clear

  1. Hydroxyurea

    Sana Biotechnology

    Thalassemia, Beta

    phase 2 small molecule active

    1 trial

  2. I-124-CLR1404

    Cellectar Biosciences

    Glioblastoma

    phase 2 small molecule terminated

    1 trial

  3. I-131-CLR1404 Injection

    Cellectar Biosciences

    Glioma

    phase 2 small molecule terminated

    1 trial

  4. IBI3016

    Innovent Biologics (Suzhou) Co.

    Hypertension

    phase 2 small molecule active

    2 trials

  5. IBUPROFEN , DEXAMETHASONE , FAMOTIDINE , SODIUM CHLORIDE , mRNA-3927, PARACETAMOL , CETIRIZINE

    Moderna Biotech Spain

    Propionic Acidemia

    phase 2 small molecule active

    1 trial

  6. ICP-022

    Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd

    Systemic Lupus Erythematosus

    phase 2 small molecule completed

    1 trial

  7. ICP-022

    Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd

    Mantle Cell Lymphoma

    phase 2 small molecule active

    1 trial

  8. IDE574

    IDEAYA Biosciences

    ER+, HER 2- Breast Cancer

    phase 2 small molecule active

    1 trial

  9. IDE849

    IDEAYA Biosciences

    Small-cell Lung Cancer

    phase 2 small molecule active

    1 trial

  10. IMX-110 combined with Tislelizumab

    Immix Biopharma

    Advanced Solid Tumor

    phase 2 small molecule active

    1 trial

  11. INBRX-106 - Hexavalent OX40 agonist antibody

    Inhibrx Biosciences

    Solid Tumor

    phase 2 small molecule active

    1 trial

  12. INBRX-109

    Inhibrx Biosciences

    Conventional Chondrosarcoma

    phase 2 small molecule active

    1 trial

  13. IO102

    IO Biotech

    NSCLC

    phase 2 mab completed

    1 trial

  14. IO102-IO103

    IO Biotech

    Melanoma

    phase 2 small molecule active

    2 trials

  15. IO102-IO103 in combination with pembrolizumab

    IO Biotech

    Lung Cancer Non Small Cell

    phase 2 small molecule completed

    1 trial

  16. IO102-IO103, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    IO Biotech

    Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN), Metastatic Urothelial Bladder Cancer (mUBC), Metastatic Non-Small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  17. IOBENGUANE (123I) , 68Ga-SSO120

    AXIM BIOTECHNOLOGIES, INC.

    neuroblastoma

    phase 2 small molecule active

    1 trial

  18. IOBENGUANE (123I) , [18F]meta-fluorobenzylguanidine

    AXIM BIOTECHNOLOGIES, INC.

    (suspision on) Neuroblastoma

    phase 2 small molecule active

    1 trial

  19. IOV-3001

    Iovance Biotherapeutics B.V.

    Unresectable Melanoma

    phase 2 mab active

    1 trial

  20. IOV-4001

    Iovance Biotherapeutics B.V.

    Unresectable Melanoma

    phase 2 mab active

    1 trial

  21. IRINOTECAN, CALCIUM LEVOFOLINATE, ivonescimab, FOLINIC ACID, OXALIPLATIN, PACLITAXEL, FLUOROURACIL

    Ningbo Cancer Hospital

    Metastatic or locally advanced irresectable (stage IV) gastric cancer (GC) or esophagogastric junction cancer (EGJC), with and without actionable biomarker (HER2/Claudin18.2)

    phase 2 small molecule active

    1 trial

  22. IRX4204

    IO Biotech

    Psoriasis

    phase 2 small molecule on hold

    1 trial

  23. IVPT

    BRIGHT MINDS BIOSCIENCES INC.

    Substance Use Disorders

    phase 2 other completed

    1 trial

  24. Ibudilast

    BRIGHT MINDS BIOSCIENCES INC.

    Methamphetamine Dependence

    phase 2 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources